What does this research mean for the field?

Varenicline is underutilized for tobacco smoking cessation in adults with newly diagnosed peripheral artery disease. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to explore how often patients with newly diagnosed peripheral artery disease use varenicline for quitting smoking.

February 25, 2026JAMA Network Open2 citationsOpen Access

Rate of Pharmacotherapy for Tobacco Smoking Cessation in Patients With New Peripheral Artery Disease

View Full Paper

KCK. Roger Cohen MJMegan S. Jarvis OAOmid Ameli

Key Points

This study aims to explore how often patients with newly diagnosed peripheral artery disease use varenicline for quitting smoking.
Conducted a cross-sectional analysis using US insurance claims data
Focused on adults with newly diagnosed peripheral artery disease
Assessed the rate of varenicline prescriptions for smoking cessation
Identified the percentage of patients using varenicline for smoking cessation
Showed a potential gap in pharmacotherapy rates among patients
Highlighted variability in treatment adherence in the target population

Abstract

This cross-sectional study uses US insurance claims data to examine the rate of varenicline use for tobacco smoking cessation among adults with newly diagnosed peripheral artery disease.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/699e90eff5123be5ed04e1bd https://doi.org/10.1001/jamanetworkopen.2025.58244

Ask AI

Helpful

Bookmark

View Full Paper

February 25, 2026JAMA Network Open2 citationsOpen Access

Rate of Pharmacotherapy for Tobacco Smoking Cessation in Patients With New Peripheral Artery Disease

View Full Paper

KCK. Roger Cohen MJMegan S. Jarvis OAOmid Ameli

Key Points

This study aims to explore how often patients with newly diagnosed peripheral artery disease use varenicline for quitting smoking.
Conducted a cross-sectional analysis using US insurance claims data
Focused on adults with newly diagnosed peripheral artery disease
Assessed the rate of varenicline prescriptions for smoking cessation
Identified the percentage of patients using varenicline for smoking cessation
Showed a potential gap in pharmacotherapy rates among patients
Highlighted variability in treatment adherence in the target population

Abstract

This cross-sectional study uses US insurance claims data to examine the rate of varenicline use for tobacco smoking cessation among adults with newly diagnosed peripheral artery disease.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/699e90eff5123be5ed04e1bd https://doi.org/10.1001/jamanetworkopen.2025.58244

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper